AVH Stock Overview
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AVH from our risk checks.
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.80 |
| 52 Week High | US$4.41 |
| 52 Week Low | US$2.34 |
| Beta | 1.6 |
| 1 Month Change | -0.36% |
| 3 Month Change | -0.36% |
| 1 Year Change | -5.08% |
| 3 Year Change | 33.97% |
| 5 Year Change | -68.18% |
| Change since IPO | 16.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVH | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0.7% | 3.7% | 5.4% |
| 1Y | -5.1% | -7.1% | -0.02% |
Return vs Industry: AVH exceeded the Australian Biotechs industry which returned -7.1% over the past year.
Return vs Market: AVH underperformed the Australian Market which returned -0% over the past year.
Price Volatility
| AVH volatility | |
|---|---|
| AVH Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 4.1% |
Stable Share Price: AVH has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AVH's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 260 | Jim Corbett | avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.
AVITA Medical, Inc. Fundamentals Summary
| AVH fundamental statistics | |
|---|---|
| Market cap | AU$375.28m |
| Earnings (TTM) | -AU$97.34m |
| Revenue (TTM) | AU$101.12m |
3.7x
P/S Ratio-3.9x
P/E RatioIs AVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVH income statement (TTM) | |
|---|---|
| Revenue | US$64.25m |
| Cost of Revenue | US$9.09m |
| Gross Profit | US$55.16m |
| Other Expenses | US$117.00m |
| Earnings | -US$61.84m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.34 |
| Gross Margin | 85.85% |
| Net Profit Margin | -96.26% |
| Debt/Equity Ratio | 939.0% |
How did AVH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 01:59 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AVITA Medical, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Laura McGuigan | B. Riley Securities, Inc. |